前瞻性多中心观察研究--BYCROSS动脉粥样硬化切除术的血管重建方案。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS CVIR Endovascular Pub Date : 2023-12-05 DOI:10.1186/s42155-023-00404-8
Dominik Liebetrau, Joerg Teßarek, Florian Elger, Sebastian Zerwes, Viktoria Peters, Christian Scheurig-Münkler, Alexander Hyhlik-Dürr
{"title":"前瞻性多中心观察研究--BYCROSS动脉粥样硬化切除术的血管重建方案。","authors":"Dominik Liebetrau, Joerg Teßarek, Florian Elger, Sebastian Zerwes, Viktoria Peters, Christian Scheurig-Münkler, Alexander Hyhlik-Dürr","doi":"10.1186/s42155-023-00404-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The BYCROSS™ device is a novel device intended for use in atherectomy of the peripheral arterial disease (PAD). With the BYCROSS™ atherectomy system, also prolonged calcifying lesions can be treated in a minimally invasive manner, which was previously reserved for bypass surgery. The aim of this study is to collect additional clinical data on safety and performance of the BYCROSS™ from patients undergoing revascularization of severely stenotic or occluded peripheral arterial vessels with the BYCROSS™.</p><p><strong>Methods and design: </strong>This is an investigator-initiated national prospective multicenter observational study in patients with PAD. Sixty patients (20 per center) with PAD with stenosis higher than 80% or complete occlusion (de novo or recurrent stenosis) of vessels below the aortic bifurcation (min 3 mm vessel diameter) will be recruited. Three vascular surgery centers are participating in the study. The primary efficacy endpoint is procedural success, defined as passage of the occlusion through the BYCROSS device, and safety outcomes, explicated as freedom from device-related serious adverse events (SADEs). Secondary endpoints include primary and secondary patency rates, change in Rutherford classification, and freedom from amputation at 3 and 12 months.</p><p><strong>Discussion: </strong>The BYCROSS atherectomy system may be a novel device for the minimally invasive treatment of prolonged calcified lesions previously reserved for bypass surgery. This national prospective multicenter observational study could represent another step in demonstrating the efficancy and safety of this device for treatment of PAD.</p><p><strong>Trial registration: </strong>#DRKS00029947 (who.int). PROTOCOL APPROVAL ID: #22-0047(Ethics Committee at Ludwig-Maximilians-University Munich).</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697923/pdf/","citationCount":"0","resultStr":"{\"title\":\"Revascularization with BYCROSS atherectomy device- protocol of a prospective multicenter observational study.\",\"authors\":\"Dominik Liebetrau, Joerg Teßarek, Florian Elger, Sebastian Zerwes, Viktoria Peters, Christian Scheurig-Münkler, Alexander Hyhlik-Dürr\",\"doi\":\"10.1186/s42155-023-00404-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The BYCROSS™ device is a novel device intended for use in atherectomy of the peripheral arterial disease (PAD). With the BYCROSS™ atherectomy system, also prolonged calcifying lesions can be treated in a minimally invasive manner, which was previously reserved for bypass surgery. The aim of this study is to collect additional clinical data on safety and performance of the BYCROSS™ from patients undergoing revascularization of severely stenotic or occluded peripheral arterial vessels with the BYCROSS™.</p><p><strong>Methods and design: </strong>This is an investigator-initiated national prospective multicenter observational study in patients with PAD. Sixty patients (20 per center) with PAD with stenosis higher than 80% or complete occlusion (de novo or recurrent stenosis) of vessels below the aortic bifurcation (min 3 mm vessel diameter) will be recruited. Three vascular surgery centers are participating in the study. The primary efficacy endpoint is procedural success, defined as passage of the occlusion through the BYCROSS device, and safety outcomes, explicated as freedom from device-related serious adverse events (SADEs). Secondary endpoints include primary and secondary patency rates, change in Rutherford classification, and freedom from amputation at 3 and 12 months.</p><p><strong>Discussion: </strong>The BYCROSS atherectomy system may be a novel device for the minimally invasive treatment of prolonged calcified lesions previously reserved for bypass surgery. This national prospective multicenter observational study could represent another step in demonstrating the efficancy and safety of this device for treatment of PAD.</p><p><strong>Trial registration: </strong>#DRKS00029947 (who.int). PROTOCOL APPROVAL ID: #22-0047(Ethics Committee at Ludwig-Maximilians-University Munich).</p>\",\"PeriodicalId\":52351,\"journal\":{\"name\":\"CVIR Endovascular\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697923/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CVIR Endovascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s42155-023-00404-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CVIR Endovascular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42155-023-00404-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:BYCROSS™ 设备是一种用于外周动脉疾病(PAD)动脉粥样硬化切除术的新型设备。使用 BYCROSS™ 动脉粥样硬化切除术系统,还能以微创方式治疗长期钙化病变,而这在以前只有搭桥手术才能实现。本研究的目的是收集使用 BYCROSS™ 对严重狭窄或闭塞的外周血管进行血管再通治疗的患者有关 BYCROSS™ 安全性和性能的更多临床数据:这是一项由研究者发起的针对 PAD 患者的全国性前瞻性多中心观察研究。将招募 60 名(每个中心 20 名)主动脉分叉以下血管狭窄超过 80% 或完全闭塞(新生或复发性狭窄)的 PAD 患者(血管直径最小为 3 毫米)。三家血管外科中心参与了这项研究。主要疗效终点是手术成功率(定义为闭塞通过 BYCROSS 装置)和安全性结果(定义为未发生与装置相关的严重不良事件 (SADE))。次要终点包括主要和次要通畅率、卢瑟福分级的变化以及3个月和12个月后无截肢:讨论:BYCROSS 动脉瘤切除系统可能是一种新型设备,可用于微创治疗以前只能通过搭桥手术治疗的长期钙化病变。这项全国性的前瞻性多中心观察研究可以证明该设备在治疗 PAD 方面的有效性和安全性:试验注册:#DRKS00029947 (who.int)。试验注册:#DRKS00029947 (who.int):#22-0047(慕尼黑路德维希-马克西米利安大学伦理委员会)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Revascularization with BYCROSS atherectomy device- protocol of a prospective multicenter observational study.

Background: The BYCROSS™ device is a novel device intended for use in atherectomy of the peripheral arterial disease (PAD). With the BYCROSS™ atherectomy system, also prolonged calcifying lesions can be treated in a minimally invasive manner, which was previously reserved for bypass surgery. The aim of this study is to collect additional clinical data on safety and performance of the BYCROSS™ from patients undergoing revascularization of severely stenotic or occluded peripheral arterial vessels with the BYCROSS™.

Methods and design: This is an investigator-initiated national prospective multicenter observational study in patients with PAD. Sixty patients (20 per center) with PAD with stenosis higher than 80% or complete occlusion (de novo or recurrent stenosis) of vessels below the aortic bifurcation (min 3 mm vessel diameter) will be recruited. Three vascular surgery centers are participating in the study. The primary efficacy endpoint is procedural success, defined as passage of the occlusion through the BYCROSS device, and safety outcomes, explicated as freedom from device-related serious adverse events (SADEs). Secondary endpoints include primary and secondary patency rates, change in Rutherford classification, and freedom from amputation at 3 and 12 months.

Discussion: The BYCROSS atherectomy system may be a novel device for the minimally invasive treatment of prolonged calcified lesions previously reserved for bypass surgery. This national prospective multicenter observational study could represent another step in demonstrating the efficancy and safety of this device for treatment of PAD.

Trial registration: #DRKS00029947 (who.int). PROTOCOL APPROVAL ID: #22-0047(Ethics Committee at Ludwig-Maximilians-University Munich).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CVIR Endovascular
CVIR Endovascular Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
2.30
自引率
0.00%
发文量
59
期刊最新文献
Feasibility of an antegrade-retrograde single-sheath inverse technique via vertical puncture in dysfunctional hemodialysis arteriovenous fistula angioplasty. Correction: Interventional solutions for post‑surgical problems: a lymphatic leaks review Carbon dioxide-enhanced angiography for detection of colonic diverticular bleeding and clinical outcomes Investigating the effects of percutaneous endovascular aneurysm repair for abdominal aortic aneurysm on the lumen size of the common femoral artery Transjugular antegrade transvenous obliteration, with and without portal decompression, for management of rectal variceal hemorrhage.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1